Literature DB >> 3954730

Trans-stimulation and trans-inhibition of uridine efflux from human erythrocytes by permeant nucleosides.

S M Jarvis.   

Abstract

The ability of nucleoside permeants to accelerate the efflux of uridine from human erythrocytes has been compared. In contrast to uridine, 2-chloroadenosine acted as a trans-inhibitor of uridine efflux from fresh human erythrocytes, and adenosine had little effect. These results are consistent with the lower maximum velocity for influx of 2-chloroadenosine and adenosine as compared with uridine and demonstrate that trans acceleration experiments do not discriminate between transported and non-transported permeants for the human erythrocyte nucleoside carrier.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3954730      PMCID: PMC1153021          DOI: 10.1042/bj2330295

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  11 in total

1.  Mediated transport of nucleosides in human erythrocytes. Accelerative exchange diffusion of uridine and thymidine and specificity toward pyrimidine nucleosides as permeants.

Authors:  C E Cass; A R Paterson
Journal:  J Biol Chem       Date:  1972-05-25       Impact factor: 5.157

2.  Nucleoside transport. I. A mediated process in human erythrocytes.

Authors:  J M Oliver; A R Paterson
Journal:  Can J Biochem       Date:  1971-02

3.  Transport of uridine in human red blood cells. Demonstration of a simple carrier-mediated process.

Authors:  Z I Cabantchik; H Ginsburg
Journal:  J Gen Physiol       Date:  1977-01       Impact factor: 4.086

Review 4.  Nucleoside transport in animal cells.

Authors:  J D Young; S M Jarvis
Journal:  Biosci Rep       Date:  1983-04       Impact factor: 3.840

5.  Inward fluxes of adenosine in erythrocytes and cultured cells measured by a quenched-flow method.

Authors:  A R Paterson; E R Harley; C E Cass
Journal:  Biochem J       Date:  1984-12-15       Impact factor: 3.857

6.  Azomycin riboside, a sugar homologue of misonidazole with favorable radiosensitizing properties.

Authors:  S M Jarvis; J D Chapman; J Ngan-Lee; K A Rutledge; P J Barr; A R Paterson
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

7.  Nucleoside transport in human and sheep erythrocytes. Evidence that nitrobenzylthioinosine binds specifically to functional nucleoside-transport sites.

Authors:  S M Jarvis; J D Young
Journal:  Biochem J       Date:  1980-08-15       Impact factor: 3.857

8.  Inhibition of adenosine uptake in human erythrocytes by adenosine-5'-carboxamides, xylosyladenine, dipyridamole, hexobendine, and p-nitrobenzylthioguanosine.

Authors:  K Turnheim; B Plank; N Kolassa
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

9.  Nucleoside transport in human erythrocytes. A simple carrier with directional symmetry in fresh cells, but with directional asymmetry in cells from outdated blood.

Authors:  S M Jarvis; J R Hammond; A R Paterson; A S Clanachan
Journal:  Biochem J       Date:  1983-02-15       Impact factor: 3.857

10.  2-Chloroadenosine, a permeant for the nucleoside transporter.

Authors:  S M Jarvis; B W Martin; A S Ng
Journal:  Biochem Pharmacol       Date:  1985-09-15       Impact factor: 5.858

View more
  3 in total

1.  Differences in trans-stimulated chloroquine efflux kinetics are linked to PfCRT in Plasmodium falciparum.

Authors:  Cecilia P Sanchez; Petra Rohrbach; Jeremy E McLean; David A Fidock; Wilfred D Stein; Michael Lanzer
Journal:  Mol Microbiol       Date:  2007-04       Impact factor: 3.501

Review 2.  Membrane transport and the antineoplastic action of nucleoside analogues.

Authors:  F M Sirotnak; J R Barrueco
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

3.  Effects of phorbol, dexamethasone and starvation on 3-O-methyl-D-glucose transport by rat thymocytes. Modulation of transport by altered trans effects.

Authors:  R J Naftalin; R J Rist
Journal:  Biochem J       Date:  1990-01-01       Impact factor: 3.857

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.